Studies upon the toxicity of polyethylene glycol coated lipid vesicles: Acute hemodynamic effects, pyrogenicity and complement activation

Journal of Liposome Research

Volumn 8, Issue 4, 1998, Pages 537-550

  Utkhede, Deepank R ^a   Tilcock, Colin P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complement; Hemodynamic; Polyethylene glycol; Pyrogen; Toxicity

Indexed keywords

LIPOSOME; MACROGOL; PYROGEN;

ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT ACTIVATION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEVER; HEMODYNAMICS; LIPID VESICLE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0032420380     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.3109/08982109809039936     Document Type: Article

References (30)

1. Utkhede, D. and Tilcock, C. 1998. Effect of lipid dose on the biodistribution and clearance kinetics of PEG-coated technetium labeled lipid vesicles. Journal of Liposome Research (in press).
2. Storm, G., Oussoren, C., Peeters, P.A.M. and Barenholz, Y., Tolerability of Liposomes in vivo in Liposome Technology, Vol. III. Gregoriadis, G. (ed.), pp. 345-383, CRC Press, Boca Raton, FL. 1993.
3. Marjan, J., Xie, Z. and Devine, D.V. 1994. Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochimica et Biophysica Acta 1192(1):35-44.
4. Devine, D.V., Wong, K., Serrano, K., Chonn, A. and Cullis, P. 1994. Liposomes-complement interactions in rat serum: implications for liposome survival studies. Biochimica et Biophysica Acta 1191(2):43-51.
5. Liu, D., Liu, F. and Song, Y.K. 1995. Recognition and clearance of liposomes containing phosphatidyl serine are mediated by serum opsonin. Biochimica et Biophysica Acta 1235:140-146.
6. Oja, C.D., Semple, S.C., Chonn, A. and Cullis, P.R. 1996. Influence of dose on liposome clearance: critical role of blood proteins. Biochimica et Biophysica Acta 1281:31-37.
7. Gabizon, A., Catane, R., Uziely, B., Kaufmann, B., Safra, T., Cohen, R., Martin, F., Huang, A. and Barenholz, Y. 1994. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol-coated liposomes. Cancer Research 54:987-992.
8. Sturzl, M., Zietz, C., Eisenburg, B., Goebel, F.D., Gillitzer, R., Hofschneider, P.H. and Bogner, J.R. 1994. Liposomal doxorubicin in the treatment of Kaposi's sarcoma: clinical, histological and cell biological evaluation. Research in Virology 145(3): 261-269.
9. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F.M. and Gabizon, A. 1995. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary Phase I studies. J Clin Oncology 13(7):1777-1785.
10. Goebel, F.D., Goldstein, D., Goos, M., Jablonowski, H. and Stewart, J.S. 1996. Efficacy and safety of Stealth liposomal doxorubicin in AIDS related Kaposi's sarcoma. The International SL-DOX Study Group. Brit J Cancer 73(8):989-994.
11. Alberts, D.S. and Garcia, D.J. 1997. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 54(Suppl 4):30-35.
12. Working, P.K. and Dayan, A.D. 1996. Pharmacological-Toxicological Expert Report. Caelyx™. (Stealth Liposomal Doxorubicin HCl) Human and Exper Toxicol 15(9):752-785.
13. Szebeni, J., Spielberg, H., Cliff, R.O., Wassef, N.M., Rudolph, A.S. and Alving, C.R. 1997. Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1. Artifical Cell, Blood Substitutes, and Immobilization Biotechnology 25(4):347-355.
14. Harashima, H., Sakata, K., Funato, K. and Kiwada, H. 1994. Enhanced hepatic uptake of liposomes through complement activation depending upon the size of the vesicles. J Pharmaceutical Research 11:402-406.
15. Sone, Y., Nicolaysen, A. and Staub, N.C. 1997. Effect of particles on sheep lung hemodynamics parallels depletion and recovery of intravascular macrophages. J Appl Physiology 83(5):1499-1507.
16. Allen, T.M. and Smuckler, E.A. 1985. Liver pathology accompanying chronic liposome administration in mice. Research. Communications in Chemical Pathology and Pharmacology 65:185-190.
17. Szebeni, J., Wassef, N.M., Rudolph, A.S. and Alving, C.R. 1995. Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. Artifical Cell, Blood Substitutes, and Immobilization Biotechnology 23(3): 355-363.
18. Guencheva, G., Popova, P., Daivkova, G., Mincheva, V., Mihailova, S., Bogdanov, A., Pacelli, E. and Auteri, A. 1992. Determination of cytokine release after in vivo and in vitro administration of Deodan (a preparation from Lactobacillus bulgarius "LB51") by the rabbit pyrogen test. Immunopharmacology 14(8):1429-1436.
19. Minano, F.J., Fernandez-Alonso, A., Benamar, K., Myers, R.D., Sancibrian, M., Ruiz, R.M. and Armengol, J.A. 1996. Macrophage inflammatory protein-1b (MIP-1b) produced endogenously in brain during E. coli fever in rats. European Journal of Neuroscience 8:424-428.
20. Pyrogen Testing in US Pharmacopeia National Formulary (USPNF), 22nd Edition, pp. 1515-1518. 1990.
21. Rabinovici, R., Rudolph, A.S., Vernick, J. and Feuerstein, G. 1994. Lyophilized liposome encapsulated hemoglobin: evaluation of hemodynamic, biochemical and hematologic responses. Critical Care Medicine 22(3):480-485.
22. Weary, M. 1984. Pyrogen testing of parenteral products-status report. Parenteral Science and Technology 38(1):20-23.
23. Cradock, J.C., Vishnuvajjala, B.R., Chin, T.F., Hochstein, H.D. and Ackerman, S.K. 1986. Uridine-induced hyperthermia in the rabbit. Journal of Pharmacy and Pharmacology 38:226-229.
24. Dinarello, C.A., Elin, J., Chedid, L. and Wolff, S.M. 1978. The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. Journal of Infectious Disease 138(6):760-767.
25. Kanter, P.M., Bullard, G.A., Pilkiewicz, F.G., Mayer, L.D., Cullis, P.R. and Pavelic, Z.P. 1993. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 7(1):85-96.
26. Amsterdam, E.A., Stahl, G.L., Pan, H-L., Rendig, S.V., Flethcher, M.P. and Longhurst, J.C. 1995. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. American Journal of Physiology 268:H448-H457.
27. Gardinali, M., Conciato, L., Cafaro, C. and Agostoni, A. 1995. Complement system in coronary heart disease: a review. Immunopharmacology 30:105-117.
28. Steurer, G., Yang, P., Rao, V., Mohl, W., Glogar, D. and Smetana, R. 1996. Acute myocardial infarction, reperfusion injury and intravenous magnesium therapy: basic concepts and clinical implications. American Heart Journal 132:478-82.
29. Sodee, D.B. Special in vitro procedures in Principles and Practice of Nuclear Medicine (Early, P.J. and Sodee, D.B. eds.),. pp. 725-738, Mosby, St. Louis, Missouri. 1995.
30. Kawana, S., Wachi, J., Nakayama, M. and Namiki, A. 1995. Comparison of haemodynamic changes induced by sevflurane and halothane in pediatric patients. Canadian Journal of Anesthesia 42(7):603-607.